

Global Cell and Gene Therapy Cold Chain Logistics Market Report and Forecast 2023-2031

Market Report | 2023-06-13 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Cell and Gene Therapy Cold Chain Logistics Market Report and Forecast 2023-2031

Global Cell and Gene Therapy Cold Chain Logistics Market Outlook

The global cell and gene therapy cold chain logistics market was valued at USD 1.6 billion in 2022, driven by the increasing adoption of cell and gene therapies across the globe. The market size is anticipated to grow at a CAGR of 15.59% during the forecast period of 2023-2031 to achieve a value of USD 6 billion by 2031.

Cell and Gene Therapy Cold Chain Logistics: Introduction

Cell and gene therapies have revolutionized the field of medicine by offering innovative treatment options for various diseases and conditions. These therapies involve the use of living cells or genetic materials to target and treat specific disorders. However, the transportation and storage of these therapies' present unique challenges due to their sensitive nature and requirement for strict temperature control. This is where cell and gene therapy cold chain logistics come into play.

Cell and gene therapy cold chain logistics refer to the specialized processes and infrastructure required to maintain the integrity and efficacy of these therapies throughout their journey from manufacturing facilities to the patient's bedside. The primary goal is to ensure that the therapies remain within their required temperature range, typically cryogenic or ultra-low temperature conditions, to preserve their quality and effectiveness.

Key Trends in the Cell and Gene Therapy Cold Chain Logistics Market

Key trends in cell and gene therapy cold chain logistics include:

- Advancements in Temperature-Controlled Packaging: There is a continuous development of advanced packaging solutions, such as cryogenic shippers and insulated containers, that provide optimal temperature control during transportation. These packaging solutions are designed to minimize temperature fluctuations and maintain the required conditions for extended periods.

- Monitoring and Data Management: Real-time monitoring systems and data management platforms play a crucial role in ensuring the integrity of cell and gene therapies. These technologies enable continuous temperature monitoring, data logging, and alert systems to identify and mitigate any deviations or potential risks during transportation. This allows for proactive intervention and

timely decision-making to maintain the therapy's quality.

- Regulatory Compliance: The regulatory landscape surrounding cell and gene therapies is evolving, and compliance with regulations and guidelines is of utmost importance. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have specific requirements for cold chain logistics, including documentation, validation, and quality management. Key trends focus on meeting these regulatory standards and adopting best practices to ensure compliance and patient safety.

Cell and Gene Therapy Cold Chain Logistics Market Segmentations

Market Breakup by Component

- Cryogenic Shippers
- Cryogenic Storage Freezers
- -□Ultra Low Freezers
- -□Cold Chain Management Systems
- Shipment and Storage Medium
- -□Cryogenic Packout Kits
- Others

Market Breakup by Services Offered

- Transportation
- -□Storage
- -□Packaging

Market by Mode of Transportation

- -∏Air
- -∏Ground
- -□Water

Market Breakup by Holding Temperature Range

- -∏Cryogenic
- Refrigerated
- -∏Ambient
- -[Others

Market Breakup by End User

- Pharmaceutical and Biotechnology Companies
- -□Academic and Research Institutes
- -∏Others

Market Breakup by Region

- ¬North America
- -□Europe
- -∏Asia Pacific
- -□Latin America
- -□Middle East and Africa

Scotts International, EU Vat number: PL 6772247784

Cell and Gene Therapy Cold Chain Logistics Market Scenario

The market for cell and gene therapy cold chain logistics is experiencing significant growth and is expected to expand further in the coming years. The increasing adoption of cell and gene therapies as well as advancements in biotechnology and regenerative medicine are driving the demand for robust and efficient cold chain logistics solutions.

The market is characterized by the presence of several players offering specialized services in cell and gene therapy cold chain logistics. These players include logistics and transportation companies, packaging manufacturers, monitoring and data management solution providers, and cryopreservation technology developers. They collaborate with pharmaceutical and biotech companies, research institutions, and healthcare providers to ensure the safe and reliable transportation of cell and gene therapies.

In conclusion, the market for cell and gene therapy cold chain logistics is a vital component of the healthcare industry, enabling the safe and efficient delivery of innovative treatments. The market introduction involves the establishment of specialized facilities and the deployment of advanced technologies to meet the unique requirements of cell and gene therapies. With the increasing adoption of these therapies and advancements in the field, the market is expected to witness continuous growth and development.

Cell and Gene Therapy Cold Chain Logistics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows: -\BioLife Solutions, Inc.

- -□United Parcel Service (Marken)
- Amerisource Bergen Corporation (World Courier)
- -□Catalent, Inc.
- Cryoport, Inc.
- -□Biostor Ltd.
- Thermo Fisher Scientific Inc.
- -□Life Science Group Ltd (LSG)
- Yourway Biopharma Services Company
- Bertelsmann SE & Co. KGaA (Arvato Supply Chain Solutions)
- -□Be The Match BioTherapies

*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1[Preface
- 1.1 Objectives of the Study
- 1.2□Key Assumptions
- 1.3 Report Coverage Key Segmentation and Scope
- 1.4□Research Methodology
- 2 Executive Summary
- 3∏Global Cell and Gene Therapy Cold Chain Logistics Market Overview
- 3.1∏Global Cell and Gene Therapy Cold Chain Logistics Market Historical Value (2016-2022)
- 3.2∏Global Cell and Gene Therapy Cold Chain Logistics Market Forecast Value (2023-2031)
- 4□Global Cell and Gene Therapy Cold Chain Logistics Market Dynamics
- 4.1 Market Drivers and Constraints

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2□SWOT Analysis
- 4.3 Porter's Five Forces Model
- 4.4 Ney Demand Indicators
- 4.5 Rey Price Indicators
- 4.6 Industry Events, Initiatives, and Trends
- 4.7 Value Chain Analysis
- 5 Global Cell and Gene Therapy Cold Chain Logistics Market Segmentation
- 5.1 Global Cell and Gene Therapy Cold Chain Logistics Market by Component
- 5.1.1 Market Overview
- 5.1.2 Cryogenic Shippers
- 5.1.3 Cryogenic Storage Freezers
- 5.1.4 Ultra Low Freezers
- 5.1.5 Cold Chain Management Systems
- 5.1.6 Shipment and Storage Medium
- 5.1.7 Cryogenic Packout Kits
- 5.1.8 Others
- 5.2 Global Cell and Gene Therapy Cold Chain Logistics Market by Services Offered
- 5.2.1 Market Overview
- 5.2.2 Transportation
- 5.2.3 Storage
- 5.2.4 Packaging
- 5.3 Global Cell and Gene Therapy Cold Chain Logistics Market by Mode of Transportation
- 5.3.1 | Market Overview
- 5.3.2∏Air
- 5.3.3 Ground
- 5.3.4 Water
- 5.4∏Global Cell and Gene Therapy Cold Chain Logistics Market by Holding Temperature Range
- 5.4.1 Market Overview
- 5.4.2 Cryogenic
- 5.4.3 Refrigerated
- 5.4.4 ☐ Ambient
- 5.4.5 | Others
- 5.5∏Global Cell and Gene Therapy Cold Chain Logistics Market by End User
- 5.5.1 Market Overview
- 5.5.2 Pharmaceutical and Biotechnology Companies
- 5.5.3 ☐ Academic and Research Institutes
- 5.5.4 Others
- 5.6 Global Cell and Gene Therapy Cold Chain Logistics Market by Region
- 5.6.1 Market Overview
- 5.6.2 North America
- 5.6.3 Europe
- 5.6.4

 ☐ Asia Pacific
- 5.6.5 \ Latin America
- 5.6.6 Middle East and Africa
- 6 North America Cell and Gene Therapy Cold Chain Logistics Market
- 6.1 Market Share by Country
- 6.2∏United States of America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 6.3 Canada
- 7 Europe Cell and Gene Therapy Cold Chain Logistics Market
- 7.1 Market Share by Country
- 7.2 United Kingdom
- 7.3 Germany
- 7.4∏France
- 7.5∏Italy
- 7.6 Others
- 8[Asia Pacific Cell and Gene Therapy Cold Chain Logistics Market
- 8.1 Market Share by Country
- 8.2∏China
- 8.3∏apan
- 8.4∏India
- 8.5∏ASEAN
- 8.6∏Australia
- 8.7∏Others
- 9 Latin America Cell and Gene Therapy Cold Chain Logistics Market
- 9.1 Market Share by Country
- 9.2□Brazil
- 9.3 Argentina
- 9.4□Mexico
- 9.5 Others
- 10 Middle East and Africa Cell and Gene Therapy Cold Chain Logistics Market
- 10.1 Market Share by Country
- 10.2∏Saudi Arabia
- 10.3 United Arab Emirates
- 10.4∏Nigeria
- 10.5 South Africa
- 10.6 Others
- 11 Patent Analysis
- 11.1 Analysis by Type of Patent
- 11.2

 ☐ Analysis by Publication year
- 11.3 Analysis by Issuing Authority
- 11.4

 ☐ Analysis by Patent Age
- 11.5

 ☐ Analysis by CPC Analysis
- 11.6

 ☐ Analysis by Patent Valuation
- 11.7

 ☐ Analysis by Key Players
- 12□Grants Analysis
- 12.1 Analysis by year
- 12.2 \square Analysis by Amount Awarded
- 12.3

 ☐ Analysis by Issuing Authority
- 12.4

 ☐ Analysis by Grant Application
- 12.5

 ☐ Analysis by Funding Institute
- 12.6 Analysis by NIH Departments
- 12.7 Analysis by Recipient Organization

Scotts International. EU Vat number: PL 6772247784

- 13 Funding Analysis
- 13.1

 ☐ Analysis by Funding Instances
- 13.2

 ☐ Analysis by Type of Funding
- 13.3 Analysis by Funding Amount
- 13.4

 ☐ Analysis by Leading Players
- 13.5

 ☐ Analysis by Leading Investors
- 13.6 Analysis by Geography
- 14 Partnership and Collaborations Analysis
- 14.1

 ☐ Analysis by Partnership Instances
- 14.2 Analysis by Type of Partnership
- 14.3 Analysis by Leading Players
- 14.4

 ☐ Analysis by Geography
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1∏US FDA
- 15.1.2□EU EMA
- 15.1.3 INDIA CDSCO
- 15.1.4∏APAN PMDA
- 15.1.5 Others
- 16 Supplier Landscape
- 16.1 BioLife Solutions, Inc.
- 16.1.1 Financial Analysis
- 16.1.2 Product Portfolio
- 16.1.3 Demographic Reach and Achievements
- 16.1.4 Mergers and Acquisitions
- 16.1.5□Certifications
- 16.2 United Parcel Service (Marken)
- 16.2.1∏Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.5 Certifications
- 16.3 Amerisource Bergen Corporation (World Courier)
- 16.3.1∏Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4□Mergers and Acquisitions
- $16.3.5 \\ \square Certifications$
- 16.4

 ☐ Catalent, Inc.
- 16.4.1 Financial Analysis
- 16.4.2∏Financial Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Mergers and Acquisitions
- 16.4.5 Certifications
- 16.5

 ☐ Atelerix Ltd.

Scotts International, EU Vat number: PL 6772247784

- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Mergers and Acquisitions
- 16.5.5 Certifications
- 16.6 Cryoport, Inc.
- 16.6.1□Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Mergers and Acquisitions
- 16.6.5 Certifications
- 16.7∏Biostor Ltd.
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Mergers and Acquisitions
- 16.7.5 Certifications
- 16.8 Thermo Fisher Scientific Inc.
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9

 ☐ Life Science Group Ltd (LSG)
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Mergers and Acquisitions
- 16.9.5 Certifications
- 16.10 \text{ Yourway Biopharma Services Company}
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic Reach and Achievements
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 Bertelsmann SE & Co. KGaA (Arvato Supply Chain Solutions)
- 16.11.1□Financial Analysis
- 16.11.2 Product Portfolio
- $16.11.3 \\ \square Demographic \ Reach \ and \ Achievements$
- 16.11.4□Mergers and Acquisitions
- 16.11.5 Certifications
- 16.12 Be The Match BioTherapies
- 16.12.1□Financial Analysis
- 16.12.2 Product Portfolio
- 16.12.3 Demographic Reach and Achievements
- 16.12.4□Mergers and Acquisitions
- 16.12.5 Certifications

Scotts International, EU Vat number: PL 6772247784

17 Global Cell and Gene Therapy Cold Chain Logistics Market - Distribution Model (Additional Insight)

17.1 Overview

17.2 Potential Distributors

17.3 Key Parameters for Distribution Partner Assessment

18 Key Opinion Leaders (KOL) Insights (Additional Insight)

19 Company Competitiveness Analysis (Additional Insight)

19.1 Very Small Companies

19.2□Small Companies

19.3 Mid-Sized Companies

19.4□Large Companies

19.5 Very Large Companies

20 Payment Methods (Additional Insight)

20.1 Government Funded

20.2 Private Insurance

20.3 Out-of-Pocket

^{*}Additional insights provided are customisable as per client requirements.



Global Cell and Gene Therapy Cold Chain Logistics Market Report and Forecast 2023-2031

Market Report | 2023-06-13 | 140 pages | EMR Inc.

To place an Order w	ith Scotts International:	
☐ - Print this form		
Complete the r	elevant blank fields and sign	
Send as a scar	ned email to support@scotts-international.com	
ORDER FORM:		
Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
	VAT	-
	T-1-	ı İ
*Please circle the relev	Tota vant license option. For any questions please contact support@scotts-international.com or 0048 603	
□** VAT will be added	vant license option. For any questions please contact support@scotts-international.com or 0048 603 3 at 23% for Polish based companies, individuals and EU based companies who are unable to provide a	394 346.
□** VAT will be added Email*	vant license option. For any questions please contact support@scotts-international.com or 0048 603 3 at 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone*	394 346.
** VAT will be added Email* First Name*	vant license option. For any questions please contact support@scotts-international.com or 0048 603 3 at 23% for Polish based companies, individuals and EU based companies who are unable to provide a	394 346.
	vant license option. For any questions please contact support@scotts-international.com or 0048 603 3 at 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone*	394 346.
** VAT will be added Email* First Name*	vant license option. For any questions please contact support@scotts-international.com or 0048 603 3 at 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone*	394 346.
** VAT will be added Email* First Name* Job title*	vant license option. For any questions please contact support@scotts-international.com or 0048 603 3 at 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone* Last Name*	394 346.
** VAT will be added Email* First Name* Job title* Company Name*	vant license option. For any questions please contact support@scotts-international.com or 0048 603 3 at 23% for Polish based companies, individuals and EU based companies who are unable to provide a Phone* Last Name* EU Vat / Tax ID / NIP number*	394 346.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature

1	